N-Acetylproline

N-Acetylproline

SCHEMBL358379

CC(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACE P12821 10/20 0.54
REN P00797 3/20 0.54
LMNA P02545 2/20 0.54
HSD17B10 Q99714 2/20 0.54
CYP2C19 P33261 1/20 0.54
KDM4E B2RXH2 1/20 0.54
F2 P00734 1/20 0.54
LTA4H P09960 1/20 0.54
MAPT P10636 1/20 0.54
PEPD P12955 1/20 0.54
ALOX15 P16050 1/20 0.54
PTGS1 P23219 1/20 0.54
HTR2A P28223 1/20 0.54
PTGS2 P35354 1/20 0.54
HRH1 P35367 1/20 0.54
THPO P40225 1/20 0.54
PMP22 Q01453 1/20 0.54
ACE2 Q9BYF1 1/20 0.54
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-Acetylproline SCHEMBL428476 1.00 ACE (0.54) ACERENLMNAHSD17B10CYP2C19
N-Acetylproline SCHEMBL428477 1.00 ACE (0.54) ACERENLMNAHSD17B10CYP2C19
N-Acetylproline SCHEMBL6469164 0.98 ACE (0.53) ACERENLMNAHSD17B10CYP2C19
N-Acetylproline SCHEMBL1375025 0.98 ACE (0.53) ACERENLMNAHSD17B10CYP2C19
N-Acetylproline SCHEMBL1375029 0.98 ACE (0.53) ACERENLMNAHSD17B10CYP2C19
SCHEMBL5860164 0.94 ACE (0.49) ACERENLMNAHSD17B10CYP2C19
SCHEMBL7054783 0.94 ACE (0.49) ACERENLMNAHSD17B10CYP2C19
SCHEMBL1840265 0.94 ACE (0.49) ACERENLMNAHSD17B10CYP2C19
SCHEMBL19566169 0.92 ACE (0.56) ACERENLMNAHSD17B10CYP2C19
SCHEMBL22423638 0.92 ACE (0.56) ACERENLMNAHSD17B10CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658228-A1 ECO-BIOLOGICAL COSMETIC COMPOSITION SUITABLE FOR REDUCING THE SIGNS OF CUTANEOUS AGEING Thorel, Jean-Noël (FR) 2025-12-10 EP claimed
CN-120064663-A Metabolic marker for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application 中国医学科学院阜外医院 2025-05-30 CN claimed
EP-3615069-B1 N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE TO REDUCE THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES AMGEN INC (US) 2025-05-28 EP claimed
CN-119523841-A Transdermal composition with whitening and freckle removing effects and preparation method thereof 广州御清堂化妆品有限公司 2025-02-28 CN claimed
CN-119517408-A Method for establishing death prediction model of new-onset type 2 diabetes and application 中南大学湘雅二医院 2025-02-25 CN claimed
US-12103979-B2 N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides AMGEN INC. (US) 2024-10-01 US claimed
US-12076432-B2 Method of repairing oxidatively treated hair CONOPCO, INC. (US) 2024-09-03 US claimed
CN-118542948-A Nanometer medicinal preparation for treating sepsis, and its preparation method and application 四川大学 2024-08-27 CN claimed
WO-2024161085-A1 ECO-BIOLOGICAL COSMETIC COMPOSITION SUITABLE FOR REDUCING THE SIGNS OF CUTANEOUS AGEING NAOS INSTITUTE OF LIFE SCIENCE (FR) 2024-08-08 WO claimed
CN-117721474-A Cleaning agent for chip after chemical mechanical polishing, preparation method and application thereof 江苏奥首材料科技有限公司 2024-03-19 CN claimed
EP-0508133-B1 Method of preparation of L-Carnitine from D,L-Carnitine nitrile salts DEGUSSA (DE) 1995-02-15 EP claimed
WO-1995001990-A1 HEMOREGULATORY PENTA- OR HEXAPEPTIDES NYCOMED PHARMA A.S (NO) 1995-01-19 WO claimed
WO-1994027627-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1994-12-08 WO claimed
EP-0416282-B1 Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use DEGUSSA (DE) 1994-09-14 EP claimed
US-5284872-A Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof SCHWARZ PHARMA AG (DE) 1994-02-08 US claimed
US-5219741-A Reacting in the presence of microbiologically produced N-acyl-L-proline acylase DEGUSSA AG (DE) 1993-06-15 US claimed
US-5166426-A PROCESS FOR PRODUCING L-CARNITINE FROM D,L-CARNITINE NITRILE SALTS DEGUSSA AG (DE) 1992-11-24 US claimed
EP-0508133-A2 Method of preparation of L-Carnitine from D,L-Carnitine nitrile salts DEGUSSA AG (DE) 1992-10-14 EP claimed
US-5120652-A Synthesis of proline from acyl derivatives; thermostable DEGUSSA AG (DE) 1992-06-09 US claimed
US-4085207-A AND AT LEAST ONE OF N-ACYL-L-TRYPTOPHANS AND N-ACYL-L-PROLINES OTSUKA PHARMACEUTICAL FACTORY, INC. (JA) 1978-04-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12103979-B2 N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides ARGLU1, PNISR, DNPEP ACE 1472/4885REN 1633/4885LMNA 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.